ABSI
NASDAQAbsci Corporation
Price$8.29+0.52 (+6.69%)
01:30 PM07:45 PM
News · 26 weeks67-23%
2026-01-182026-07-12
Mix3290d
- Insider11(34%)
- SEC Filings8(25%)
- Other5(16%)
- Earnings4(13%)
- Analyst2(6%)
- Leadership2(6%)
Latest news
25 items- PRAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
- PRAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T
- INSIDERDirector Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- PRThe Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in ParallelA wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the
- INSIDERChief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)4 - Absci Corp (0001672688) (Issuer)
- SECSEC Form 8-K filed by Absci Corporation8-K - Absci Corp (0001672688) (Filer)
- SECSEC Form 424B5 filed by Absci Corporation424B5 - Absci Corp (0001672688) (Filer)
- PRAbsci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial InvestorsEli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions. The gross proceeds from the offering, bef
- SECAbsci Corporation filed SEC Form 8-K: Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027 VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
- INSIDERAmendment: Director Szela Mary T was granted 8,400 shares (SEC Form 4)4/A - Absci Corp (0001672688) (Issuer)
- PRMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug DiscoveryMindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover
- INSIDERDirector Mcginnis Karen K was granted 10,100 shares, increasing direct ownership by 26% to 48,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Szela Mary T was granted 10,100 shares (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Pangalos Menelas N was granted 10,100 shares, increasing direct ownership by 4% to 242,408 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Van Houten Frans was granted 10,100 shares, increasing direct ownership by 16% to 73,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Rabinovitsj Daniel A was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- INSIDERDirector Sirosh Joseph was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- SECAbsci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Absci Corp (0001672688) (Filer)
- ANALYSTLeerink Partners initiated coverage on Absci Corporation with a new price targetLeerink Partners initiated coverage of Absci Corporation with a rating of Outperform and set a new price target of $12.00
- INSIDERCFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,319 shares, decreasing direct ownership by 2% to 491,464 units (SEC Form 4) to satisfy withholding tax4 - Absci Corp (0001672688) (Issuer)
- ANALYSTBTIG Research initiated coverage on Absci Corporation with a new price targetBTIG Research initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
- PRAbsci to Participate in Upcoming Investor ConferencesVANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference (New York, NY)Presentation on Wednesday, June 3rd at 7:35 a.m. Eastern Time / 4:35 a.m. Pacific Time Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL)Presentation on Tuesday, June 9th at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time Interested parties may access live and archived webcasts of the presentations on the company's
- INSIDERDirector Pangalos Menelas N bought $200,748 worth of shares (37,453 units at $5.36), increasing direct ownership by 19% to 232,308 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
ABSI FAQ
7 questionsWhat does Absci Corporation do?
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.Where does ABSI stock trade?
Absci Corporation (ABSI) is listed on NASDAQ.What sector and industry is ABSI in?
Absci Corporation operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Absci Corporation go public?
Absci Corporation (ABSI) completed its IPO in 2021.What are analysts saying about ABSI?
Absci Corporation has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1200.00 price target on 2026-06-04. Recent price targets range from $432.00 to $1200.00.What companies are similar to ABSI?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare ABSI side-by-side with any of them on Quantisnow.How can I track ABSI on Quantisnow?
Quantisnow aggregates Absci Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABSI to receive live email and push alerts on every new disclosure.